Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRE and Nivolumab in Metastatic Pancreatic Cancer (CHECKPOINT)
NCT05435053Phase 2Terminated
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in pancreatic cancer (PC). Started Sep 2022; status: terminated.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05435053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435053.